Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Humacyte (HUMA) from a "hold" to a "sell" in a report issued Sunday.
• Despite that downgrade, the Street consensus remains a "Moderate Buy" — seven analysts rate the stock Buy and one rates it Sell, with a consensus price target of $8.29.
• HUMA trades around $1.11 with a market cap of about $207.9M, carries a negative EPS and high debt-to-equity (2.97); it slightly beat quarterly EPS estimates but missed on revenue and is forecast to report about -1.27 EPS for the year.

Humacyte (NASDAQ:HUMA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Sunday.

Other equities research analysts have also issued research reports about the company. UBS Group reaffirmed a "buy" rating on shares of Humacyte in a report on Monday, December 1st. Benchmark decreased their price target on Humacyte from $14.00 to $11.00 and set a "buy" rating on the stock in a research note on Thursday, November 13th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Thursday, November 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Humacyte in a research report on Monday, December 15th. Finally, BTIG Research restated a "buy" rating and set a $6.00 target price on shares of Humacyte in a research report on Friday, November 21st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.29.

Humacyte Stock Performance

Shares of HUMA opened at $1.11 on Friday. The stock has a market capitalization of $207.87 million, a P/E ratio of -4.83 and a beta of 1.90. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a 1 year low of $1.06 and a 1 year high of $6.77. The company's fifty day moving average is $1.40 and its two-hundred day moving average is $1.81.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.92 million. On average, sell-side analysts predict that Humacyte will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Lazari Capital Management Inc. bought a new stake in shares of Humacyte in the 2nd quarter worth about $27,000. Prudential Financial Inc. acquired a new position in Humacyte in the second quarter worth about $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter valued at about $28,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Humacyte during the second quarter valued at approximately $30,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Humacyte during the second quarter valued at approximately $32,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.